Is it Time for Process Excellence in Pharma R&D?
For years pharmaceutical companies could rake in high margins on drugs that were protected by patents. But as many patents have expired or are near expiration – so much so that the industry is calling it the “patent cliff” – pharma companies are having to look much harder at how they can streamline processes in R&D to save time and money.
In this Process Perspectives podcast, Andrew Parson, VP Preclinical Drug Development at GlaxoSmithKline and Gera...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.